Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Products under Development by Stage of Development | 8 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Products under Development by Therapy Area | 9 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Products under Development by Indication | 10 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Products under Development by Companies | 13 | 2 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Products under Development by Universities/Institutes | 15 | 2 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Companies Involved in Therapeutics Development | 24 | 7 |
| Amryt Pharma plc | 24 | 1 |
| Boehringer Ingelheim GmbH | 25 | 1 |
| Crinetics Pharmaceuticals, Inc. | 26 | 1 |
| Ipsen S.A. | 27 | 1 |
| OctreoPharm Sciences GmbH | 28 | 1 |
| Progenics Pharmaceuticals, Inc. | 29 | 1 |
| Strongbridge Biopharma plc | 30 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drug Profiles | 31 | 15 |
| AP-102 Drug Profile | 31 | 1 |
| COR-005 Drug Profile | 32 | 3 |
| Edotreotide Labeled Yttrium 90 Drug Profile | 35 | 2 |
| FX-125L Drug Profile | 37 | 2 |
| lanreotide acetate Drug Profile | 39 | 4 |
| OPS-201 Drug Profile | 43 | 1 |
| Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain Drug Profile | 44 | 1 |
| Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors Drug Profile | 45 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Dormant Projects | 46 | 3 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Discontinued Products | 49 | 1 |
| Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Featured News &Press Releases | 50 | 11 |
| Jul 27, 2016: Supplemental Application Filed for Somatuline in Japan for Additional Indication of Neuroendocrine Tumors | 50 | 1 |
| Jun 04, 2016: Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome | 50 | 1 |
| Jun 02, 2016: Ipsen Announces Data Presentations of Somatuline Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting | 51 | 1 |
| May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology | 52 | 1 |
| Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium | 53 | 1 |
| Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumors | 54 | 1 |
| May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting | 54 | 1 |
| Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain | 55 | 1 |
| Apr 14, 2015: MHRA approves Ipsen s Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumors | 56 | 1 |
| Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium | 57 | 1 |
| Dec 16, 2014: Ipsen s Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors | 57 | 1 |
| Nov 06, 2014: Ipsen Announces FDA Approval of a New Delivery Device for Somatuline Depot (lanreotide) Injection | 58 | 1 |
| Sep 01, 2014: Ipsen Announces Acceptance of Filings for Somatuline in the Treatment of GEP-NET1s in the US with Priority Review and in Europe | 59 | 1 |
| Jul 16, 2014: New England Journal of Medicine Publishes Ipsen s Somatuline CLARINET Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors | 59 | 1 |
| Jul 01, 2014: Ipsen submits marketing authorization applications in the US and Europe for Somatuline (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors | 60 | 1 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |
